Current state of biology and diagnosis of clonal mast cell diseases in adults

International Journal of Laboratory Hematology

Volumn 34, Issue 5, 2012, Pages 445-460

  Alvarez Twose, I ^a,b   Morgado, J M ^a,b   Sanchez Munoz L ^a,b   Garcia Montero A ^b,c   Mollejo, M ^a,b   Orfao, A ^b,c   Escribano, L ^a,b  

^a HOSPITAL VIRGEN DE LA SALUD   (Spain)

^b Red Española de Mastocitosis REMA   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Biology; Diagnosis; Mast cells; Mastocytosis

Indexed keywords

BETA 2 MICROGLOBULIN; CARBOXYPEPTIDASE; CD2 ANTIGEN; COMPLEMENT RECEPTOR; FC RECEPTOR; IMMUNOGLOBULIN E; INTERLEUKIN 2 RECEPTOR ALPHA; LACTATE DEHYDROGENASE; PROTEIN TYROSINE KINASE; STEM CELL FACTOR; TRYPTASE;

ALLERGIC REACTION; ANAPHYLAXIS; ANTIGEN DETECTION; BASOPHIL; BLOOD CELL COUNT; BONE MARROW BIOPSY; CLONAL VARIATION; CODON; COMPUTER ASSISTED TOMOGRAPHY; CYTOPATHOLOGY; DUAL ENERGY X RAY ABSORPTIOMETRY; ECHOGRAPHY; EFFECTOR CELL; EOSINOPHILIA; FLOW CYTOMETRY; FOLLOW UP; GENE DELETION; GENE FREQUENCY; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; INFLAMMATION; MAST CELL; MAST CELL DEGRANULATION; MASTOCYTOSIS; MEDIATOR RELEASE; MORPHOMETRICS; MUTATIONAL ANALYSIS; NATURAL KILLER CELL; PATHOGENESIS; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SKIN EXAMINATION;

EID: 85027917636     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/j.1751-553X.2012.01427.x     Document Type: Review

References (107)

1. Horny HP, Metcalfe DD, Bennet JM, Bain BJ, Akin C, Escribano L, Valent P. Mastocytosis. In: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). Lyon: IARC; 2008: 54-63.
2. Valent P, Horny HP, Escribano L, Longley BJ, Li CL, Schwartz LB, Marone G, Núñez R, Akin C, Sotlar K, Sperr W, Wolff K, Brunning RD, Parwaresch RM, Austen KF, Lennert AK, Metcalfe D, Vardiman JW, Bennet JM. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001;25:603-25.
3. Valent P, Akin C, Escribano L, Fodinger M, Hartmann K, Brockow K, Castells M, Sperr WR, Kluin-Nelemans HC, Hamdy NA, Lortholary O, Robyn J, van DJ, Sotlar K, Hauswirth AW, Arock M, Hermine O, Hellmann A, Triggiani M, Niedoszytko M, Schwartz LB, Orfao A, Horny HP, Metcalfe DD. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007;37:435-53.
4. Escribano L, Alvarez-Twose I, Sanchez-Munoz L, Garcia-Montero A, Nunez R, Almeida J, Jara-Acevedo M, Teodosio C, Garcia-Cosio M, Bellas C, Orfao A. Prognosis in adult indolent systemic mastocytosis: a long-term study of the Spanish Network on Mastocytosis in a series of 145 patients. J Allergy Clin Immunol 2009;124:514-21.
5. Sanchez-Munoz L, Alvarez-Twose I, Garcia-Montero AC, Teodosio C, Jara-Acevedo M, Pedreira CE, Matito A, Morgado JM, Sanchez ML, Mollejo M, Gonzalez-de-Olano D, Orfao A, Escribano L. Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol 2011a;24:1157-68.
6. Escribano L, Garcia-Montero A, Sanchez-Munoz L, Teodosio C, Alvarez-Twose I, Jara-Acevedo M, Morgado JM, Almeida J, Orfao A. Diagnosis of adult mastocytosis: role for bone marrow analysis. In: Laboratory Hematology Practice. Kottke-Marchant K, Davis BH (eds). London: Wiley-Blackwell; 2012: 388-98, in press.
7. Horny HP, Sillaber C, Menke D, Kaiserling E, Wehrmann M, Stehberger B, Chott A, Lechner K, Lennert K, Valent P. Diagnostic value of immunostaining for tryptase in patients with mastocytosis. Am J Surg Pathol 1998;22:1132-40.
8. Sperr W, Escribano L, Jordan JH, Schernthaner GH, Kundi M, Horny HP, Valent P. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res 2001a;25:529-36.
9. Sperr WR, Jordan JH, Baghestanian M, Kiener HP, Samorapoompichit P, Semper H, Hauswirth A, Schernthaner GH, Chott A, Natter S, Kraft D, Valenta R, Schwartz LB, Geissler K, Lechner K, Valent P. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001b;98:2200-9.
10. Sperr WR, Jordan JH, Fiegl M, Escribano L, Bellas C, Dirnhofer S, Semper H, Simonitsch-Klupp I, Horny HP, Valent P. Serum tryptase levels in patients with mastocytosis: correlation with mast cell burden and implication for defining the category of disease. Int Arch Allergy Immunol 2002b;128:136-41.
11. Sperr WR, Stehberger B, Wimazal F, Baghestanian M, Schwartz LB, Kundi M, Semper H, Jordan JH, Chott A, Drach J, Jäger U, Geissler K, Greschniok A, Horny HP, Lechner K, Valent P. Serum tryptase measurements in patients with myelodysplastic syndromes. Leuk Lymphoma 2002c;43:1097-105.
12. Klion AD, Noel P, Akin C, Law MA, Gilliland DG, Cools J, Metcalfe DD, Nutman TB. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood 2003;101:4660-6.
13. Escribano L, Diaz-Agustin B, López A, López RN, García-Montero A, Almeida J, Prados A, Angulo M, Herrero S, Orfao A, Spanish NM. Immunophenotypic analysis of mast cells in mastocytosis: when and how to do it. Proposals of the Spanish network on mastocytosis (REMA). Cytometry B Clin Cytom 2004;58:1-8.
14. Akin C, Fumo G, Yavuz AS, Lipsky PE, Neckers L, Metcalfe DD. A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib. Blood 2004b;103:3222-5.
15. Akin C, Escribano L, Núñez R, García-Montero A, Angulo M, Orfao A, Metcalfe DD. Well-differentiated systemic mastocytosis: a new disease variant with mature mast cell phenotype and lack of codon 816 c-kit mutations. J Allergy Clin Immunol 2004a;113:S327.
16. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, Aldanondo I, Sanchez L, Dominguez M, Botana LM, Sanchez-Jimenez F, Sotlar K, Almeida J, Escribano L, Orfao A. KIT mutation in mast cells and other bone marrow haematopoietic cell lineages in systemic mast cell disorders. A prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006;108:2366-72.
17. Teodosio C, Garcia-Montero AC, Jara-Acevedo M, Sanchez-Munoz L, Alvarez-Twose I, Nunez R, Schwartz LB, Walls AF, Escribano L, Orfao A. Mast cells from different molecular and prognostic subtypes of systemic mastocytosis display distinct immunophenotypes. J Allergy Clin Immunol 2010;125:719-26.
18. Alvarez-Twose I, González P, Morgado JM, Jara-Acevedo M, Sánchez-Muñoz L, Matito A, Mollejo M, Orfao A, Escribano L. Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis. J Clin Oncol 2012, Epub ahead of print.
19. Bonadonna P, Perbellini O, Passalacqua G, Caruso B, Colarossi S, Dal FD, Castellani L, Bonetto C, Frattini F, Dama A, Martinelli G, Chilosi M, Senna G, Pizzolo G, Zanotti R. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol 2009;123:680-6.
20. Alvarez-Twose I, Gonzalez de Olano D, Sanchez-Munoz L, Matito A, Esteban-Lopez MI, Vega A, Mateo MB, Alonso Diaz de Durana MD, de la Hoz B, Del Pozo MD, Caballero T, Rosado A, Sanchez-Matas I, Teodosio C, Jara-Acevedo M, Mollejo M, Garcia-Montero A, Orfao A, Escribano L. Clinical, biological and molecular characteristics of systemic mast cell disorders presenting with severe mediator-related symptoms. J Allergy Clin Immunol 2010;125:1269-78.
21. Sonneck K, Florian S, Mullauer L, Wimazal F, Fodinger M, Sperr WR, Valent P. Diagnostic and subdiagnostic accumulation of mast cells in the bone marrow of patients with anaphylaxis: monoclonal mast cell activation syndrome. Int Arch Allergy Immunol 2006;142:158-64.
22. Alvarez-Twose I, Gonzalez de OD, Sanchez-Munoz L, Teodosio C, Jara-Acevedo M, Sanchez-Matas I, Matito A, Garcia-Montero A, Orfao A, Escribano L. Clinical, biological and molecular characteristics of mast cell activation disorders: a prospective study in 62 patients by the Spanish Network on Mastocytosis (REMA). J Allergy Clin Immunol 2009;123:S141.
23. Johnson MR, Verstovsek S, Jorgensen JL, Manshouri T, Luthra R, Jones DM, Bueso-Ramos CE, Medeiros LJ, Huh YO. Utility of the World Heath Organization classification criteria for the diagnosis of systemic mastocytosis in bone marrow. Mod Pathol 2009;22:50-7.
24. Li L, Krilis SA. Mast-cell growth and differentiation. Allergy 1999;54:306-12.
25. Blume-Jensen P, Claesson-Welsh L, Siegbahn A, Zsebo KM, Westermark B, Heldin CH. Activation of the human c-kit product by ligand-induced dimerization mediates circular actin reorganization and chemotaxis. EMBO J 1991;10:4121-8.
26. Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol 2005;6:135-42.
27. Okayama Y, Kawakami T. Development, migration, and survival of mast cells. Immunol Res 2006;34:97-115.
28. Kitamura Y, Oboki K, Ito A. Molecular mechanisms of mast cell development. Immunol Allergy Clin North Am 2006;26:387-405.
29. Kawakami T, Galli SJ. Regulation of mast-cell and basophil function and survival by IgE. Nat Rev Immunol 2002;2:773-86.
30. Hamaguchi Y, Kanakura Y, Fijita J, Takeda SI, Nakano T, Tarui S, Honjo T, Kitamura Y. Interleukin 4 as an essential factor for in vitro clonal growth of murine connective tissue-type mast cells. J Exp Med 1987;165:268-73.
31. Matsuda H, Kannan Y, Ushio H, Kiso Y, Kanemoto T, Suzuki H, Kitamura Y. Nerve growth factor induces development of connective tissue- type mast cells in vitro from murine bone marrow cells. J Exp Med 1991;174:7-14.
32. Kitamura Y. Heterogeneity of mast cells and phenotypic change between subpopulations. Annu Rev Immunol 1989;7:59-76.
33. Metcalfe DD, Baram D, Mekori YA. Mast cells. Physiol Rev 1997;77:1033-79.
34. Yarden Y, Kuang WJ, Yang Feng T, Coussens L, Munemitsu S, Dull TJ, Chen E, Schlessinger J, Francke U, Ullrich A. Human proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. EMBO J 1987;6:3341-51.
35. Spritz RA, Strunk KM, Lee ST, Lu-Kuo JM, Ward DC, Le PD, Altherr MR, Dorman TE, Moir DT. A YAC contig spanning a cluster of human type III receptor protein tyrosine kinase genes (PDGFRA-KIT-KDR) in chromosome segment 4q12. Genomics 1994;22:431-6.
36. Orfao A, Garcia-Montero AC, Sanchez L, Escribano L. Recent advances in the understanding of mastocytosis: the role of KIT mutations. Br J Haematol 2007;138:12-30.
37. Hartmann K, Wardelmann E, Ma YS, Merkelbach-Bruse S, Preussner LM, Woolery C, Baldus SE, Heinicke T, Thiele J, Buettner R, Longley BJ. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology 2005;129:1042-6.
38. Zhang LY, Smith ML, Schultheis B, Fitzgibbon J, Lister TA, Melo JV, Cross NCP, Cavenagh JD. A novel K5091 mutation of KIT identified in familial mastocytosis - in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006;30:373-8.
39. Tang X, Boxer M, Drummond A, Ogston P, Hodgins M, Burden AD. A germline mutation in KIT in familial diffuse cutaneous mastocytosis. J Med Genet 2004;41:89-93.
40. Nakagomi N, Hirota S. Juxtamembrane-type c-kit gene mutation found in aggressive systemic mastocytosis induces imatinib-resistant constitutive KIT activation. Lab Invest 2007;87:365-71.
41. Furitsu T, Tsujimura T, Tono T, Ikeda H, Kitayama H, Koshimizu U, Sugahara H, Butterfield JH, Ashman LK, Kanayama Y, Matsuzawa Y, Kitamura Y, Kanakura Y. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92:1736-44.
42. Tefferi A, Levine RL, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Finke CM, Mullally A, Li CY, Pardanani A, Gilliland DG. Frequent TET2 mutations in systemic mastocytosis: clinical, KITD816V and FIP1L1-PDGFRA correlates. Leukemia 2009;23:900-4.
43. Wilson TM, Maric I, Simakova O, Bai Y, Chan EC, Olivares N, Carter M, Maric D, Robyn J, Metcalfe DD. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica 2011;96:459-63.
44. Worobec AS, Akin C, Scott LM, Metcalfe DD. Mastocytosis complicating pregnancy. Obstet Gynecol 2000;95:391-5.
45. Escribano L, Akin C, Castells M, Orfao A, Metcalfe D. Mastocytosis: current concepts in diagnosis and treatment. Ann Hematol 2002a;81:677-90.
46. Escribano L, Akin C, Castells M, Schwartz LB. Current options in the treatment of mast cell mediator-related symptoms in mastocytosis. Inflamm Allergy Drug Targets 2006a;5:61-77.
47. Sanchez-Matas I, Matito A, Gonzalez de Olano D, Alvarez-Twose I, Sanchez-Munoz L, de la Hoz Caballer B, Escribano L. Prevalence of hypersensitivity reactions to nonsteroidal anti-inflamatory drugs in 212 patients with mastocytosis in Spain. Allergy 2009;64:574-5.
48. Matito A, Alvarez-Twose I, Morgado JM, Sanchez-Munoz L, Orfao A, Escribano L. Clinical impact of pregnancy in mastocytosis: a study of the Spanish Network on Mastocytosis (REMA) in 45 cases. Int Arch Allergy Immunol 2011;156:104-11.
49. Galli SJ, Dvorak AM, Dvorak HF. Basophils and mast cells: morphologic insights into their biology, secretory patterns, and function. Prog Allergy 1984;34:1-141.
50. Fukuoka Y, Xia HZ, Sanchez-Munoz LB, Dellinger AL, Escribano L, Schwartz LB. Generation of anaphylatoxins by human {beta}-tryptase from C3, C4, and C5. J Immunol 2008;180:6307-16.
51. Katz HR, Raizman MB, Gartner CS, Scott HC, Benson AC, Austen KF. Secretory granule mediator release and generation of oxidative metabolites of arachidonic acid via Fc-IgG receptor bridging in mouse mast cells. J Immunol 1991;148:868-71.
52. Lobell RB, Arm JP, Raizman MB, Austen KF, Katz HR. Intracellular degradation of Fc gamma RIII in mouse bone marrow culture-derived progenitor mast cells prevents its surface expression and associated function. J Biol Chem 1993;268:1207-12.
53. Lobell RB, Austen KF, Katz HR. FcgammaR-mediated endocytosis and expression of cell surface FcgammaRIIb1 and FcgammaRIIb2 by mouse bone marrow culture- derived progenitor mast cells. J Immunol 1994;152:811-8.
54. Marshall JS. Mast-cell responses to pathogens. Nat Rev Immunol 2004;4:787-99.
55. Castells M. Mast cell mediators in allergic inflammation and mastocytosis. Immunol Allergy Clin North Am 2006;26:465-85.
56. Schwartz LB. Tryptase: a mast cell serine protease. Methods Enzymol 1994;244:88-100.
57. Castells M, Irani AM, Schwartz LB. Evaluation of human peripheral blood leukocytes for mast cell tryptase. J Immunol 1987;138:2184-9.
58. Schwartz LB, Min HK, Ren SL, Xia HZ, Hu J, Zhao W, Moxey G, Fukuoka Y. Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, mono-mac-6 cells, and human skin-derived mast cells. J Immunol 2003;170:5667-73.
59. Weber A, Knop J, Maurer M. Pattern analysis of human cutaneous mast cell populations by total body surface mapping. Br J Dermatol 2003;148:224-8.
60. Hollmann TJ, Brenn T, Hornick JL. CD25 expression on cutaneous mast cells from adult patients presenting with urticaria pigmentosa is predictive of systemic mastocytosis. Am J Surg Pathol 2008;32:139-45.
61. Sotlar K, Horny HP, Simonitsch I, Krokowski M, Aichberger KJ, Mayerhofer M, Printz D, Fritsch G, Valent P. CD25 indicates the neoplastic phenotype of mast cells - a novel immunohistochemical marker for the diagnosis of systemic mastocytosis (SM) in routinely processed bone marrow biopsy specimens. Am J Surg Pathol 2004;28:1319-25.
62. Baumgartner C, Sonneck K, Krauth MT, Kneidinger M, Fodinger M, Hauswirth AW, Mullauer L, Valent P. Immunohistochemical assessment of CD25 is equally sensitive and diagnostic in mastocytosis compared to flow cytometry. Eur J Clin Invest 2008;38:326-35.
63. Sotlar K, Cerny-Reiterer S, Petat-Dutter K, Hessel H, Berezowska S, Mullauer L, Valent P, Horny HP. Aberrant expression of CD30 in neoplastic mast cells in high-grade mastocytosis. Mod Pathol 2011;24:585-95.
64. Maric I, Calvo KR. Mastocytosis: the new differential diagnosis of CD30-positive neoplasms. Leuk Lymphoma 2011;52:732-3.
65. Horny HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res 2001;25:543-51.
66. Horny HP, Lange K, Sotlar K, Valent P. Increase of bone marrow lymphocytes in systemic mastocytosis: reactive lymphocytosis or malignant lymphoma? Immunohistochemical and molecular findings on routinely processed bone marrow biopsy specimens. J Clin Pathol 2003;56:575-8.
67. Orfao A, Escribano L, Villarrubia J, Velasco JL, Cerveró C, Ciudad J, Navarro JL, San Miguel JF. Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples. Identification and enumeration. Am J Pathol 1996;149:1493-9.
68. Escribano L, Navalón R, Núñez R, Díaz Agustín B, Bravo P. Flow cytometry immunophenotypic analysis of human mast cells. In: Current Protocols in Cytometry. Robinson JP, Darzynkiewicz Z, Dean P, Orfao A, Rabinovitch P, Wheeless L (eds). New York: John Wiley & Sons, Inc; 2000: 6.6.1-6.18.
69. Escribano L, Diaz-Agustin B, Nunez R, Prados A, Rodriguez R, Orfao A. Abnormal expression of CD antigens in mastocytosis. Int Arch Allergy Immunol 2002b;127:127-32.
70. Escribano L, Garcia Montero AC, Nunez R, Orfao A. Flow cytometric analysis of normal and neoplastic mast cells: role in diagnosis and follow-up of mast cell disease. Immunol Allergy Clin North Am 2006b;26:535-47.
71. Sanchez-Munoz L, Teodosio C, Morgado JM, Escribano L. Immunophenotypic characterization of bone marrow mast cells in mastocytosis and other mast cell disorders. Methods Cell Biol 2011b;103:333-59.
72. Escribano L, Orfao A, Villarrubia J, Cerveró C, Velasco JL, Martin F, San Miguel JF, Navarro JL. Expression of lymphoid-associated antigens in mast cells: report of a case of systemic mast cell disease. Br J Haematol 1995;91:941-3.
73. Escribano L, Orfao A, Villarrubia J, Martín F, Madruga JI, Cuevas M, Velasco JL, Rios A, San Miguel JF. Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia. Cytometry 1997;30:98-102.
74. Escribano L, Orfao A, Villarrubia J, Díaz Agustín B, Cerveró C, Ríos A, Velasco JL, Ciudad J, Navarro JL, San Miguel JF. Immunophenotypic characterization of human bone marrow mast cells. A flow cytometric study of normal and pathological bone marrow samples. Anal Cell Pathol 1998c;16:151-9.
75. Escribano L, Díaz Agustín B, Bravo P, Navalón R, Almeida J, Orfao A. Immunophenotype of bone marrow mast cells in indolent systemic mast cell disease in adults. Leuk Lymphoma 1999;35:227-35.
76. Escribano L, Díaz Agustín B, Bellas C, Navalón R, Núñez R, Sperr W, Schernthaner G, Valent P, Orfao A. Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis. Leuk Res 2001;25:563-70.
77. Bodni RA, Sapia S, Galeano A, Kaminsky A. Indolent systemic mast cell disease: immunophenotypic characterization of bone marrow mast cells by flow cytometry. J Eur Acad Dermatol Venereol 2003;17:160-6.
78. Pardanani A, Kimlinger T, Reeder T, Li CY, Tefferi A. Bone marrow mast cell immunophenotyping in adults with mast cell disease: a prospective study of 33 patients. Leuk Res 2004;28:777-83.
79. Escribano L, Orfao A, Diaz-Agustin B, Villarrubia J, Cervero C, Lopez A, Marcos MA, Bellas C, Fernandez-Canadas S, Cuevas M, Sanchez A, Velasco JL, Navarro JL, Miguel JF. Indolent systemic mast cell disease in adults: immunophenotypic characterization of bone marrow mast cells and its diagnostic implications. Blood 1998b;91:2731-6.
80. Teodosio C, Garcia-Montero AC, Jara-Acevedo M, Alvarez-Twose I, Sanchez-Munoz L, Almeida J, Morgado JM, Matito A, Escribano L, Orfao A. An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosis. Leukemia 2011, Epub ahead of print.
81. Morgado JM, Sanchez-Munoz L, Teodosio CG, Jara-Acevedo M, Alvarez-Twose I, Matito A, Fernandez-Nunez E, Garcia-Montero A, Orfao A, Escribano L. Immunophenotyping in systemic mastocytosis diagnosis: 'CD25 positive' alone is more informative than the 'CD25 and/or CD2' WHO criterion. Mod Pathol 2012, Epub ahead of print.
82. Escribano L, Orfao A, Díaz Agustín B, Cerveró C, Herrero S, Villarrubia J, Bravo P, Torrelo A, Montero T, Valdemoro M, Velasco JL, Navarro JL, San Miguel JF. Human bone marrow mast cells from indolent systemic mast cell disease constitutively express increased amounts of the CD63 protein on their surface. Cytometry 1998a;34:223-8.
83. Cerveró C, Escribano L, Orfao A, Díaz Agustín B, Bravo P, Villarrubia J, García-Sanz R, Velasco JL, Herrera P, Vargas M, González M, Navarro JL, San Miguel JF. Expression of bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemia. Am J Hematol 1999;60:191-5.
84. Diaz-Agustin B, Escribano L, Bravo P, Herrero S, Nunez R, Navalon R, Navarro L, Torrelo A, Cantalapiedra A, Del Castillo L, Villarrubia J, Navarro JL, San Miguel JF, Orfao A. The CD69 early activation molecule is overexpressed in human bone marrow mast cells from adults with indolent systemic mast cell disease. Br J Haematol 1999;106:400-5.
85. Hauswirth AW, Escribano L, Prados A, Nunez R, Mirkina I, Kneidinger M, Florian S, Sonneck K, Vales A, Schernthaner GH, Sanchez-Munoz L, Sperr WR, Buhring HJ, Orfao A, Valent P. CD203c is overexpressed on neoplastic mast cells in systemic mastocytosis and is upregulated upon IgE receptor cross-linking. Int J Immunopathol Pharmacol 2008;21:797-806.
86. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, Metcalfe DD. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Nat Acad Sci USA 1995;92:10560-4.
87. Sotlar K, Escribano L, Landt O, Möhrle S, Herrero S, Torrelo A, Lass U, Horny HP, Bültmann B. One-step detection of c-kit point mutations using PNA-mediated PCR-clamping and hybridization probes. Am J Pathol 2003;162:737-46.
88. Kocabas CN, Yavuz AS, Lipsky PE, Metcalfe DD, Akin C. Analysis of the lineage relationship between mast cells and basophils using the c-kit D816V mutation as a biologic signature. J Allergy Clin Immunol 2005;115:1155-61.
89. Tan A, Westerman D, McArthur GA, Lynch K, Waring P, Dobrovic A. Sensitive detection of KIT D816V in patients with mastocytosis. Clin Chem 2006;52:2250-7.
90. Schumacher JA, Elenitoba-Johnson KS, Lim MS. Detection of the c-kit D816V mutation in systemic mastocytosis by allele-specific PCR. J Clin Pathol 2008;61:109-14.
91. Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, McClure RF, Li CY, Pardanani A. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009;113:5727-36.
92. Molderings GJ, Meis K, Kolck UW, Homann J, Frieling T. Comparative analysis of mutation of tyrosine kinase kit in mast cells from patients with systemic mast cell activation syndrome and healthy subjects. Immunogenetics 2010;62:721-7.
93. Kristensen T, Vestergaard H, Moller MB. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn 2011;13:180-8.
94. Sotlar K, Marafioti T, Griesser H, Theil J, Aepinus C, Jaussi R, Stein H, Valent P, Horny HP. Detection of c-kit mutation Asp 816 to Val in microdissected bone marrow infiltrates in a case of systemic mastocytosis associated with chronic myelomonocytic leukaemia. J Clin Pathol Mol Pathol 2000;53:188-93.
95. Taylor ML, Sehgal D, Raffeld M, Obiakor H, Akin C, Mage RG, Metcalfe DD. Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis. J Mol Diagn 2004;6:335-42.
96. Yavuz AS, Lipsky PE, Yavuz S, Metcalfe DD, Akin C. Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. Blood 2002;100:661-5.
97. Kopp P, Jaggi R, Tobler A, Borisch B, Oestreicher M, Sabacan L, Jameson JL, Fey MF. Clonal X-inactivation analysis of human tumours using the human androgen receptor gene (HUMARA) polymorphism: a non-radioactive and semiquantitative strategy applicable to fresh and archival tissue. Mol Cell Probes 1997;11:217-28.
98. Wu Y, Basir Z, Kajdacsy-Balla A, Strawn E, Macias V, Montgomery K, Guo SW. Resolution of clonal origins for endometriotic lesions using laser capture microdissection and the human androgen receptor (HUMARA) assay. Fertil Steril 2003;79:710-7.
99. Schwartz LB. Clinical utility of tryptase levels in systemic mastocytosis and associated hematologic disorders. Leuk Res 2001;25:553-62.
100. Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am 2006;26:451-63.
101. Sperr WR, El-Samahi A, Kundi M, Girschikofsky M, Winkler S, Lutz D, Endler G, Rumpold H, Agis H, Sillaber C, Jager U, Valent P. Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology. Eur J Clin Invest 2009;39:914-23.
102. Schwartz LB, Irani AMA. Serum tryptase and the laboratory diagnosis of systemic mastocytosis. Hematol Oncol Clin North Am 2000;14:641-57.
103. Kushnir-Sukhov NM, Brittain E, Reynolds JC, Akin C, Metcalfe DD. Elevated tryptase levels are associated with greater bone density in a cohort of patients with mastocytosis. Int Arch Allergy Immunol 2006;139:265-70.
104. Ferrer M, Nunez-Cordoba JM, Luquin E, Grattan CE, De la Borbolla JM, Sanz ML, Schwartz LB. Serum total tryptase levels are increased in patients with active chronic urticaria. Clin Exp Allergy 2010;40:1760-6.
105. Sperr WR, Hauswirth AW, Valent P. Tryptase a novel biochemical marker of acute myeloid leukemia. Leuk Lymphoma 2002a;43:2257-61.
106. Sirvent AE, Gonzalez C, Enriquez R, Fernandez J, Millan I, Barber X, Amoros F. Serum tryptase levels and markers of renal dysfunction in a population with chronic kidney disease. J Nephrol 2010;23:282-90.
107. Metcalfe DD, Schwartz LB. Assessing anaphylactic risk? Consider mast cell clonality. J Allergy Clin Immunol 2009;123:687-8.